Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
itching
Biotech
Ipsen scuttles liver disease candidates from Albireo acquisition
Ipsen has set aside the two drug candidates it picked up from the 2023 acquisition of liver disease specialist Albireo.
Darren Incorvaia
May 6, 2026 3:10pm
Mirum maps FDA path after anti-itch candidate scores ph. 2 win
May 4, 2026 10:40am
Alfasigma's $690M deal for GSK itch drug awaiting FDA decision
Mar 9, 2026 6:55am
GSK posts phase 3 itch data as it closes in on FDA approval
May 8, 2025 8:50am
GSK’s itch prospect hits mark in phase 3 liver disease trial
Nov 19, 2024 8:24am
Connect uncouples from Pfizer by scrapping eczema pact
Apr 17, 2024 6:38am
